Rob Volansky

DESTIN, Fla. — New treatments have improved outcomes in lupus, but preventing disease in the early stages remains elusive, according to a speaker at the Congress of Clinical Rheumatology East.“We have seen amazing progress in lupus,” Judith A. James, MD, PhD, executive vice president and chief medical officer of the arthritis and clinical immunology research program at Oklahoma

DESTIN, Fla. — Osteoarthritis, far from being “simply wear and tear,” demands a multifaceted management strategy, according to a speaker at the Congress of Clinical Rheumatology East.“Rheumatologists tend to be discouraged when thinking about osteoarthritis,” said Amanda E. Nelson, MD, MSCR, RhMSUS, director of the Core Center for Clinical Research at the University

Key takeaways: CGRP inhibitors used to treat migraine did not increase glaucoma risk. Monoclonal antibody CGRP inhibitors were most likely to reduce glaucoma risk.

New EULAR recommendations for the management of rheumatoid arthritis stress that disease-modifying antirheumatic drugs should not be discontinued, even

DESTIN, Fla. — The anticipated FDA approval of brepocitinib signals an important shift in dermatomyositis management, according to a speaker at the Congress of Clinical Rheumatology East.“A true highlight of the derm-rheum world is that we finally will have an FDA-approved therapy that is modern, targeted and effective in both skin and muscle disease of dermatomyositis,” said

Treatment with subcutaneous foslevodopa/foscarbidopa was associated with cost savings of more than 95,000per advanced Parkinson’s disease , according to findings in the Journal of Medical Economics. “The costs associated with advanced Parkinson's disease extend beyond direct medical expenditure,” K. Ray Chaudhuri, MD, professor of neurology at Kings College Hospital, and

Higher sensorimotor function was associated with reduced likelihood of mild cognitive impairment in two cohorts of older individuals, according to findings published in Alzheimer’s & Dementia.“Identifying precursors to mild cognitive impairment (MCI) — the transitional stage between unimpaired cognition and dementia — is a public health priority,” Amal A.

Biologics coordinators exert much control over the medications used in rheumatology clinics, with 80% reporting “significant” influence over biosimilar

Vunakizumab, a novel interleukin 17a monoclonal antibody, is superior to placebo in radiographic axial spondyloarthritis symptom improvement, according to data published in JAMA Network Open.

Low-dose aspirin initiated giant cell arteritis diagnosis reduced the risk for major adverse cardiac events at 1 and 3 years, but increased risk for major hemorrhage at 1 year, according to data published in JAMA Network Open.